I just found this out. Apparently, by testing for these 2 biomarkers, Synaps Dx, the company behind the test Discern, is able to tell if the patient has AD and distinguish it from other dementias.
Not the same thing as Cogstate, obviously - because there's the need for a skin sample to be shipped to their lab - but it's interesting that Semler Scientific invested in Synaps Dx. Semler's clients are the largest insurance companies and At-Home-Risk assessment companies in the US.
"Semler Scientific previously announced its Fall 2020 investment in another private company, now known as SYNAPS Dx, whose product is a test for early Alzheimer's disease, named Discern™. Semler Scientific believes its current products and services, and any future products or services that it may offer, positions it to provide valuable information to its customer base, which in turn permits them to better guide patient care."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)